CLINICAL_TRIALS
trial_result
· 2017-10-26
Clinical Trial Update: Regorafenib Second Line Treatment of Metastatic or Advanced Upper GI Cancers [Phase 2]
Summary
Phase 2 trial update for regorafenib as second-line therapy in metastatic or advanced upper GI cancers; study terminated with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: University of Utah | Conditions: Upper GI Cancer | Phase 2 | Status: TERMINATED | Results posted: 2017-10-26